Vulvar lichen planus is a chronic inflammatory skin condition that causes painful erosions, burning, and scarring on the vulva, and it tends to be more difficult to manage than its better-known relative, lichen sclerosus. It is driven by an autoimmune process in which the body’s own immune cells attack the skin and mucous membranes of the genital area. Because it can also involve the vagina, mouth, and other mucosal surfaces simultaneously, vulvar lichen planus often demands a broader treatment strategy than conditions that stay in one spot.
What Is Happening Under the Skin
The underlying process in vulvar lichen planus is an immune system attack on the lowest layer of the skin’s surface, called the basal layer. Research has shown that vulvar lichen planus features a pronounced autoimmune pattern: dense clusters of T cells (including CD4, CD8, and regulatory T cells) infiltrate the tissue, accompanied by elevated Th1 cytokines and high levels of a specific micro-RNA called miR-155, which is associated with immune overactivation.1PubMed. An autoimmune phenotype in vulvar lichen sclerosus and lichen planus: a Th1 response and high levels of microRNA-155 In practical terms, these immune cells erode the boundary between the outer skin and the tissue beneath it. That destruction is what produces the hallmark erosions, raw patches, and, over time, scarring that can permanently reshape the vulvar and vaginal anatomy.
Recognizing the Different Forms
Vulvar lichen planus does not always look the same. Clinicians recognize three main presentations, and understanding which type you have matters for both prognosis and treatment.
- Erosive: The most common and most symptomatic vulvar form. Red, raw, glazed patches appear on the inner vulva and vaginal entrance. The surface tissue has broken down, so contact with urine, clothing, or sexual activity causes significant pain. This form carries the highest risk of scarring.
- Classic: Small, flat-topped, violaceous (purplish) bumps with a fine white lacy pattern on the surface. This form is familiar to dermatologists who see lichen planus on other parts of the body, though it is less common on the vulva than the erosive type.
- Hypertrophic: Thickened, raised, sometimes warty-looking plaques. Under the microscope, hypertrophic lichen planus shows marked thickening of the surface layers with the same immune cell band seen in the classic type, but with more dramatic changes in the upper skin architecture.2Journal of Lower Genital Tract Disease. Clinicopathologic Diagnostic Criteria for Vulvar Lichen Planus Hypertrophic lesions can be mistaken for precancerous growths, making biopsy especially important.
Many people with vulvar lichen planus have more than one form at once, or shift between forms over the course of the disease. It is not unusual for someone to present with erosive disease on the inner surfaces and classic papules on the outer labia at the same time.
How Vulvar Lichen Planus Differs From Lichen Sclerosus
Lichen sclerosus and lichen planus are the two most common chronic inflammatory conditions of the vulva, and they are frequently confused with each other, even by clinicians. The distinction matters because their behavior, treatment targets, and complication profiles differ. Lichen sclerosus tends to produce white, parchment-like patches with atrophy and depigmentation. Lichen planus favors erosions and redness and has a notable tendency to involve mucosal surfaces that lichen sclerosus rarely touches, particularly the vagina and mouth.3PubMed. Vulval lichen sclerosus and lichen planus
Under the microscope, lichen sclerosus shows a characteristic zone of scarring beneath the skin surface (dermal sclerosis), while lichen planus features a tight band of immune cells hugging the base of the skin with destruction of the basal cells and dying keratinocytes scattered through the tissue. A ten-year comparative study found that the most reliable distinguishing feature in lichen sclerosus was diffuse dermal sclerosis (present in about three-quarters of cases), while lichen planus was best identified by its lichenoid inflammation pattern (present in roughly 86% of cases), along with dead keratinocytes and immune cells migrating up into the skin surface.4Journal of Lower Genital Tract Disease. Vulvar Lichenoid Dermatoses With Emphasis on the Distinction Between Lichen Sclerosus and Lichen Planus: A 10-Year Study Adding to the diagnostic challenge, about one in five lichen sclerosus cases showed overlapping inflammatory features that mimicked lichen planus, requiring careful pathology review to tell apart.
When More Than the Vulva Is Involved
One of the most distinctive and troublesome features of vulvar lichen planus is that it often does not stay on the vulva. The condition has a particular affinity for mucosal surfaces throughout the body. The best-described multi-site pattern is the vulvovaginal-gingival syndrome, in which painful erosions appear simultaneously on the vulva, inside the vagina, and on the gums.5JAMA Dermatology. The Vulvovaginal-Gingival Syndrome of Lichen Planus: The Clinical Characteristics of 22 Patients In a study of 22 women with this syndrome, all had gum disease (erosions or white reticulated lesions), and the majority also had erosions on the vulva and vagina.
Long-term follow-up of patients with the vulvovaginal-gingival syndrome has documented sequelae that go beyond the genital and oral areas, including narrowing of the esophagus, scarring of tear ducts and ear canals, vaginal stenosis, and fibrosis of the inner cheeks.6Journal of the American Academy of Dermatology. The vulvovaginal gingival syndrome If you have vulvar lichen planus and notice sore gums, a persistently dry or gritty-feeling mouth, or difficulty swallowing, it is worth mentioning these symptoms to your clinician, because they may be part of the same disease process.
Links to Other Autoimmune Conditions
People with vulvar lichen planus are more likely to have other autoimmune conditions than the general population. A case-control study found that about 29% of women with erosive vulvar lichen planus had at least one additional autoimmune disorder, compared with roughly 9% of controls.7Archives of Dermatology. The Association of Lichen Sclerosus and Erosive Lichen Planus of the Vulva With Autoimmune Disease: A Case-Control Study Thyroid disease was the most common companion, occurring in about 15% of the lichen planus group. Alopecia areata and celiac disease were also significantly more frequent in the lichen planus group than in controls. One patient in the study had seven concurrent autoimmune diagnoses, illustrating the degree to which immune dysregulation can cascade across organ systems.
The practical upshot is that if you are diagnosed with vulvar lichen planus, screening bloodwork for thyroid function and celiac disease is reasonable, particularly if you have symptoms like unexplained fatigue, weight changes, or chronic digestive issues.
Getting a Diagnosis
Vulvar lichen planus is notoriously underdiagnosed. Symptoms like burning, rawness, and pain with intercourse overlap with common conditions such as yeast infections, bacterial vaginosis, and vulvodynia, so many people cycle through multiple incorrect diagnoses before the right one is made. The average diagnostic delay in some published series stretches to several years.
A biopsy is the cornerstone of diagnosis. The pathologist looks for a tightly applied band of immune cells along the base of the skin, destruction of the basal layer (visible as vacuolar change, dying cells, or flattening of the normally columnar basal cells), and irregularly shaped projections of the skin surface into the tissue below.8PubMed Central. Classic and Hypertrophic Vulvar Lichen Planus These features collectively form what pathologists call a “lichenoid reaction.” For the hypertrophic subtype, additional findings include marked thickening, excess surface scale, and sometimes fibrosis in the upper tissue layer.
One common frustration: a single biopsy may be non-diagnostic if it catches a non-representative area. If clinical suspicion is high and the first biopsy is inconclusive, a repeat biopsy from the edge of an active erosion is often informative. It also helps to have the specimen reviewed by a pathologist experienced with vulvar dermatoses, since misinterpretation of vulvar biopsies is well documented.
First-Line Treatment With Topical Steroids
Ultra-potent topical corticosteroids, particularly clobetasol propionate 0.05%, are the standard first-line treatment for vulvar lichen planus, just as they are for lichen sclerosus. In lichen sclerosus, long-term clobetasol use has achieved complete remission in roughly 54–70% of patients without significant local atrophy, even over years of use.9JAMA Dermatology. Vulvar Lichen Sclerosus: Effect of Long-term Topical Application of a Potent Steroid on the Course of the Disease10PubMed Central. Treatment Options in Vulvar Lichen Sclerosus: A Scoping Review Vulvar lichen planus, however, responds less predictably to topical steroids alone, especially the erosive form. Many patients see improvement in pain and inflammation but do not achieve full clearance.
A typical regimen starts with daily application of clobetasol for several weeks, then tapers to a few times per week for maintenance. Side effects to watch for include a burning sensation from the ointment base itself, thinning of the skin with prolonged use on non-mucosal areas, and rare secondary yeast infections. On mucosal surfaces (the inner vulva and vagina), steroid-induced thinning is less of a concern than on outer skin, since these surfaces are naturally thinner and tolerate potent steroids better than keratinized skin does.
Calcineurin Inhibitors as a Second-Line Option
When topical steroids fail to control erosive vulvar lichen planus, topical calcineurin inhibitors, most commonly tacrolimus 0.1% ointment, are the usual next step. In published case reports, tacrolimus has produced visible improvement in vulvar erosions within about four weeks in patients who had previously failed not just potent steroids but also multiple systemic medications including dapsone, griseofulvin, and hydroxychloroquine.11British Journal of Dermatology. Successful treatment of erosive vulvovaginal lichen planus with topical tacrolimus Tacrolimus works by a different mechanism than steroids, targeting the calcineurin pathway in T cells rather than broadly suppressing inflammation. This makes it a useful alternative when steroid side effects accumulate or when the disease is simply not responsive to corticosteroids.
The main drawback is an initial burning sensation upon application, which can be intense on already-raw tissue. For some patients, this burning subsides within the first week or two; for others, it is intolerable. Cycling between short courses of topical steroids and tacrolimus is a common real-world approach that leverages the strengths of both.
Systemic Therapies for Refractory Disease
When topical treatments are not enough, the options shift to systemic medications, though the evidence base here is thin. A survey of dermatologists and gynecologists found that about 47% of providers reported prescribing systemic therapies for vulvar lichen planus at some point, with severe pain or itching unresponsive to topicals being the most common trigger for escalation. The most commonly used systemic agents were oral corticosteroids and methotrexate.12PubMed Central. Use of systemic therapies for vulvar lichen sclerosus and vulvovaginal lichen planus: a survey study of dermatologists and gynecologists
The reality is that no single systemic drug has strong trial evidence for vulvar lichen planus. Treatment is largely guided by case series and expert opinion, and it often takes sequential trials of different drugs before finding one that works for a given patient. A published case report illustrated this: a woman with erosive vulvar lichen planus who had failed topical therapy was treated sequentially with hydroxychloroquine (suboptimal response), mycophenolate mofetil (effective but caused intolerable muscle pain), and finally cyclosporin, which achieved complete remission that held even after the drug was stopped.13Case Reports in Women’s Health. Vulvovaginal erosive lichen planus refractory to topical therapies: What’s next? That kind of trial-and-error journey is, unfortunately, typical. High-quality randomized trials comparing systemic therapies head-to-head in vulvar lichen planus are only now being designed.14PubMed Central. The efficacy and safety of deucravacitinib compared to methotrexate, in patients with vulvar lichen planus who have failed topical therapy with potent corticosteroids
Emerging Therapies and JAK Inhibitors
Some of the most promising developments in vulvar lichen planus treatment involve drugs originally developed for other immune-mediated conditions. JAK inhibitors, a class of medications that block specific signaling pathways inside immune cells, have shown early encouraging results. A systematic review of novel therapies for vulvovaginal lichen planus found that tofacitinib (a JAK inhibitor) achieved complete resolution in about 75% of patients treated in small studies, while the biologic tildrakizumab achieved complete resolution in roughly 88% of a small group of 25 patients.15PubMed. Vulvovaginal Lichen Planus Treatment Outcomes: A Systematic Review of Novel and Established Therapies These numbers are eye-catching but come with an important caveat: they are based on very small patient groups, typically fewer than 25 people per treatment arm, and need validation in larger trials.
A case report also documented success with abrocitinib, a selective JAK 1 inhibitor currently approved for atopic dermatitis, in clearing recalcitrant hypertrophic and erosive vulvar lichen planus.16PubMed Central. Recalcitrant vulvar lichen planus cleared on abrocitinib: A case report The broader significance is that these newer drugs may fill a real gap for the substantial number of patients whose disease does not respond adequately to conventional topical or systemic therapies. However, JAK inhibitors carry their own risks, including increased susceptibility to infections and, with some formulations, cardiovascular and malignancy concerns that require careful monitoring.
Scarring, Adhesions, and Surgery
Left unchecked, erosive vulvar lichen planus progressively destroys tissue. The labia minora can shrink or fuse, the clitoral hood can seal over the clitoris (a process called phimosis), and the vaginal opening can narrow to the point where penetrative intercourse and even pelvic exams become impossible. Inside the vagina, adhesions can form bands of scar tissue that shorten or completely close off the vaginal canal.
When scarring has already occurred, medical therapy alone cannot restore the anatomy. Surgical lysis of adhesions, sometimes combined with placement of vaginal dilators and postoperative intravaginal corticosteroids, has been described as a safe and effective approach to restore vaginal length and function.17Journal of Lower Genital Tract Disease. Outcomes After Lysis of Adhesions and Dilator Placement for Treatment of Vulvovaginal Agglutination Due to Lichen Planus A surgical team experienced with vulvar lichen planus complications has published protocols emphasizing that aggressive postoperative care, including daily dilator use and ongoing topical steroids, is essential to prevent the adhesions from re-forming.18PubMed. Surgical management of vulvovaginal agglutination due to lichen planus Without this maintenance, re-scarring rates are high. This is one of the strongest arguments for early and sustained medical treatment: preventing the scarring in the first place is far easier than surgically reversing it.
Cancer Risk
Vulvar lichen planus carries a small but real risk of progressing to vulvar squamous cell carcinoma. A systematic review estimated the absolute risk at roughly 1.2%.19PubMed. Risk of Vulvar Squamous Cell Carcinoma in Lichen Sclerosus and Lichen Planus: A Systematic Review That number sounds low, but the behavior of these cancers is concerning. In a study of 38 squamous cell carcinomas arising in the setting of vulvar lichen planus, all tumors were unrelated to HPV, about 42% of patients had lymph node spread at the time of diagnosis, and nearly 40% of surgically treated patients went on to develop additional new cancers in the remaining diseased tissue. Over a third of the patients in this series died of their disease.20PubMed. Vulvar cancers in women with vulvar lichen planus: a clinicopathological study
The cancers arose in both erosive and non-erosive forms of lichen planus and were found predominantly on inner mucosal surfaces. The precursor changes were not always easy to spot and showed varied appearances under the microscope. This underscores the importance of regular follow-up examinations, including biopsy of any new or changing lesions, even when symptoms feel stable. The goal is to catch precancerous changes early, when they are still treatable with local surgery.
The Psychological and Sexual Toll
Chronic vulvar disease takes a significant toll on mental health and sexual well-being, and vulvar lichen planus may be among the hardest on quality of life. In a study of women with erosive vulvar lichen planus, about 59% reported at least a moderate impact on their daily quality of life, and roughly 14% screened positive for depression while 16% screened positive for anxiety.21PubMed. Quality of Life and Sexual Distress in Women With Erosive Vulvovaginal Lichen Planus Sexual distress was even more prevalent: about 69% of women with erosive vulvar lichen planus had clinically meaningful sexual distress scores, and quality-of-life scores correlated with both depression and sexual dissatisfaction.
Separate research confirmed significantly worse sexual function and genital self-image in women with vulvar lichen planus compared to healthy controls, along with higher anxiety scores.22PubMed. Evaluation of genital self-image and sexual dysfunction in women with vulvar lichen planus or lichen sclerosus The disease creates a cycle: pain and tissue fragility make sexual activity difficult or impossible, which strains relationships, erodes self-image, and feeds anxiety and avoidance. Breaking this cycle usually requires more than just treating the skin. Pelvic floor physiotherapy, psychosexual counseling, and use of vaginal dilators are all relevant components of care, though they remain underutilized in many clinics.
Contact Irritants and Avoidable Triggers
While vulvar lichen planus is driven by internal immune processes, external irritants can worsen symptoms and complicate management. A review of patch-test results in patients with persistent vulvar symptoms found that nearly half had positive allergic reactions, and the most common culprits were medicaments and their components, with more than half of those patients reacting to multiple allergens.23British Journal of Dermatology. Allergic contact dermatitis and vulvar dermatoses In practical terms, this means that some of the creams, ointments, or over-the-counter products a person applies to try to soothe their vulvar symptoms can actually be making things worse through allergic contact dermatitis layered on top of the underlying disease.
Common offenders include fragranced soaps and body washes, preservatives in topical medications (such as propylene glycol or chlorhexidine), dyed or scented toilet paper, laundry detergent residues on underwear, and adhesives in panty liners. Switching to bland, fragrance-free products and applying prescribed medications in their simplest base formulation can remove a layer of irritation that makes the lichen planus harder to control. If your symptoms spike unpredictably or seem worse after applying a topical treatment, a patch test through a dermatology clinic can identify whether contact allergy is complicating the picture.